Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary or recurrent biliary duct carcinoma from the proximal, middle, or distal bile ducts~* Measurable or evaluable disease that is considered resectable~* No distant metastases~  * No non-contiguous liver metastases~ * Resectable extension into adjacent liver allowed~ * No metastasis to peritoneal cavity~ * No Bismuth type 4 lesion or metastasis to celiac axis or para-aortic lymph nodes~* No tumor encasement of portal vein or hepatic artery~* No gross ascites~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* No cirrhosis~* No active cholangitis~* No fever or signs of infection in biliary drainage system~* Measurement of C-reactive protein optimal~* Bilirubin less than 3 mg/dL~Renal:~* Creatinine less than 1.5 mg/dL OR~* Creatinine clearance greater than 60 mL/min~Other:~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception during and for 3 months after study~* No weight loss greater than 20% ideal body weight~* No active duodenal or gastric ulcers~* No other prior or concurrent primary malignancy except adequately treated carcinoma in situ of the cervix or basal cell carcinoma~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).